193 related articles for article (PubMed ID: 37407431)
1. Coupling of conformational dynamics and inhibitor binding in the phosphodiesterase-5 family.
Tripathi S; Cote RH; Vashisth H
Protein Sci; 2023 Aug; 32(8):e4720. PubMed ID: 37407431
[TBL] [Abstract][Full Text] [Related]
2. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.
Biswas KH; Visweswariah SS
J Biol Chem; 2011 Mar; 286(10):8545-8554. PubMed ID: 21193396
[TBL] [Abstract][Full Text] [Related]
3. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
Corbin JD; Francis SH
Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
[TBL] [Abstract][Full Text] [Related]
4. Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.
Corbin JD; Zoraghi R; Francis SH
Cell Signal; 2009 Dec; 21(12):1768-74. PubMed ID: 19665054
[TBL] [Abstract][Full Text] [Related]
5. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
8. Catalytic Domains of Phosphodiesterase 5, 6, and 5/6 Chimera Display Differential Dynamics and Ligand Dissociation Energy Barriers.
Pattis JG; Kamal S; Li B; May ER
J Phys Chem B; 2019 Jan; 123(4):825-835. PubMed ID: 30616346
[TBL] [Abstract][Full Text] [Related]
9. Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change.
Heikaus CC; Stout JR; Sekharan MR; Eakin CM; Rajagopal P; Brzovic PS; Beavo JA; Klevit RE
J Biol Chem; 2008 Aug; 283(33):22749-59. PubMed ID: 18534985
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities.
Corbin JD; Turko IV; Beasley A; Francis SH
Eur J Biochem; 2000 May; 267(9):2760-7. PubMed ID: 10785399
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil.
Bessay EP; Blount MA; Zoraghi R; Beasley A; Grimes KA; Francis SH; Corbin JD
J Pharmacol Exp Ther; 2008 Apr; 325(1):62-8. PubMed ID: 18199808
[TBL] [Abstract][Full Text] [Related]
12. Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil.
Corbin JD; Foster TL; Bessay E; Busch J; Blount M; Francis SH
Cell Signal; 2011 May; 23(5):778-84. PubMed ID: 21187142
[TBL] [Abstract][Full Text] [Related]
13. Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.
Cahill KB; Quade JH; Carleton KL; Cote RH
J Biol Chem; 2012 Nov; 287(49):41406-16. PubMed ID: 23033484
[TBL] [Abstract][Full Text] [Related]
14. Conformation changes, N-terminal involvement, and cGMP signal relay in the phosphodiesterase-5 GAF domain.
Wang H; Robinson H; Ke H
J Biol Chem; 2010 Dec; 285(49):38149-56. PubMed ID: 20861010
[TBL] [Abstract][Full Text] [Related]
15. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity.
Francis SH; Bessay EP; Kotera J; Grimes KA; Liu L; Thompson WJ; Corbin JD
J Biol Chem; 2002 Dec; 277(49):47581-7. PubMed ID: 12359732
[TBL] [Abstract][Full Text] [Related]
17. In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.
Kayık G; Tüzün NŞ; Durdagi S
J Biomol Struct Dyn; 2017 Oct; 35(13):2830-2852. PubMed ID: 27581752
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.
Zhang T; Lai Z; Yuan S; Huang YY; Dong G; Sheng C; Ke H; Luo HB
J Med Chem; 2020 Sep; 63(17):9828-9837. PubMed ID: 32794708
[TBL] [Abstract][Full Text] [Related]
19. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
20. Identifying Phosphodiesterase-5 Inhibitors with Drug Repurposing Approach: Implications in Vasodysfunctional Disorders.
Khan MS; Mohammad HA; Shahwan M; Yadav DK; Anwar S; Shamsi A
ChemistryOpen; 2024 May; 13(5):e202300196. PubMed ID: 38060834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
